Acorda Therapeutics (NASDAQ:ACOR) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research note issued on Saturday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Price Performance

The company has a debt-to-equity ratio of 3.07, a current ratio of 0.33 and a quick ratio of 0.26. The firm has a market capitalization of $820,000.00, a PE ratio of 0.00 and a beta of 1.40. Acorda Therapeutics has a one year low of $0.61 and a one year high of $24.20. The company has a 50-day simple moving average of $11.75 and a 200 day simple moving average of $12.36.

Hedge Funds Weigh In On Acorda Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Deutsche Bank AG bought a new stake in shares of Acorda Therapeutics during the 4th quarter worth about $26,000. Prudential Financial Inc. acquired a new stake in Acorda Therapeutics in the 2nd quarter worth approximately $28,000. Geode Capital Management LLC lifted its holdings in Acorda Therapeutics by 44.8% in the 4th quarter. Geode Capital Management LLC now owns 67,669 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 20,948 shares during the last quarter. Virtu Financial LLC bought a new stake in Acorda Therapeutics during the second quarter worth approximately $68,000. Finally, Susquehanna International Group LLP grew its holdings in Acorda Therapeutics by 1,759.1% during the first quarter. Susquehanna International Group LLP now owns 218,830 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 207,059 shares during the last quarter. 12.71% of the stock is currently owned by institutional investors.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.